Exploratory study on telaprevir given every 8 h at 500 mg or 750 mg with peginterferon-alpha-2b and ribavirin in hepatitis C patients. (Q50550265)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23190247%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

title

Exploratory study on telaprevir given every 8 h at 500 mg or 750 mg with peginterferon-alpha-2b and ribavirin in hepatitis C patients (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23190247%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

1 reference

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23190247%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

19

Hiromitsu Kumada

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23190247%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

1

Fumitaka Suzuki

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23190247%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

11

Kenji Ikeda

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23190247%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

8

Masahiro Kobayashi

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23190247%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

2

Yoshiyuki Suzuki

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23190247%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

4

Norio Akuta

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23190247%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

10

Yasuji Arase

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23190247%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

3

Hitomi Sezaki

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23190247%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

6

Yusuke Kawamura

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23190247%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

14

Mariko Kobayashi

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23190247%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

9

Satoshi Saito

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23190247%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

author name string

Yuya Seko

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23190247%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

Rie Mineta

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23190247%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

Sachiyo Watahiki

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23190247%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

Yoshiyuki Nakayasu

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23190247%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

Hidetaka Tsuda

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23190247%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

Keiji Aoki

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23190247%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

Ichimaro Yamada

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23190247%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

publication date

29 November 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23190247%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23190247%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

volume

43

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23190247%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

page(s)

691-701

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23190247%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23190247%20AND%20SRC:MED&resulttype=core&format=json

Telaprevir for previously untreated chronic hepatitis C virus infection

18 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12009

Telaprevir for retreatment of HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12009

Response-guided telaprevir combination treatment for hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12009

Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12009

Efficacy and safety of telaprevir, a new protease inhibitor, for difficult-to-treat patients with genotype 1 chronic hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12009

Telaprevir and peginterferon with or without ribavirin for chronic HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12009

Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12009

Rapid loss of hepatitis C virus genotype 1b from serum in patients receiving a triple treatment with telaprevir (MP-424), pegylated interferon and ribavirin for 12 weeks.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12009

Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12009

Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholest

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12009

Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b. Sensitivity to interferon is conferred by amino acid substitutions in the NS5A region

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12009

Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12009

Functional haplotypes of PADI4, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12009

Influence of ITPA polymorphisms on decreases of hemoglobin during treatment with pegylated interferon, ribavirin, and telaprevir.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12009

Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or -2b to patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12009

IL28B but not ITPA polymorphism is predictive of response to pegylated interferon, ribavirin, and telaprevir triple therapy in patients with genotype 1 hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12009

Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12009

Dosage adjustment of ribavirin based on renal function in Japanese patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12009

Correlation of serum ribavirin concentration with pretreatment renal function estimates in patients with chronic hepatitis C receiving combination antiviral therapy with peginterferon and ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12009

A high-throughput SNP typing system for genome-wide association studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12009

21 January 2018

Identifiers

DOI

10.1111/HEPR.12009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23190247%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

1 reference